Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases

Autores
Leblanc, Jean Guy Joseph; del Carmen, Silvina Andrea; Alvarenga Lima, Fernanda; Zurita Turk, Meritxell; Miyoshi, Anderson; Azevedo, Vasco; de Moreno, Maria Alejandra
Año de publicación
2012
Idioma
inglés
Tipo de recurso
parte de libro
Estado
versión publicada
Descripción
Inflammatory bowel disease (IBD) is a term used to describe a group of intestinal disorders in which inflammation is a major feature. Although rare forms of IBD exist, these diseases normally pertain to ulcerative colitis (UC) (Head & Jurenka, 2003) and Crohn’s disease (CD) (Baumgart & Sandborn, 2007). There is evidence that these do not represent distinct conditions but rather are the same disease with shared etiological factors (Price, 1992); however, clinical manifestations (such as the exact location of the pathology or the affected individual’s immunological and constitutional endowment) are distinctive between both. Despite many years of study, the exact etiology and pathogenesis of these disorders remain unclear but great advances have been made using experimental animal models and have provided insights into the complex, multi-factorial processes and mechanisms that can result in chronic intestinal inflammation (Elson & Weaver, 2003). The aim of this chapter is to present an overview of the current expanding knowledge of the mechanisms by which lactic acid bacteria and other probiotic microorganisms participate in the prevention and treatment of IBD and how genetic engineering techniques can be used to improve their effectiveness or create novel therapeutic strains. In the following sections, the mechanisms by which these beneficial microorganisms exert their therapeutic effects, which include changes in the gut microbiota, stimulation of the host immune responses, enhancement of intestinal barrier function and reduction of the oxidative stress due to their antioxidant properties will be discussed.
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Alvarenga Lima, Fernanda. Universidade Federal de Minas Gerais; Brasil
Fil: Zurita Turk, Meritxell. Universidade Federal de Minas Gerais; Brasil
Fil: Miyoshi, Anderson. Universidade Federal de Minas Gerais; Brasil
Fil: Azevedo, Vasco. Universidade Federal de Minas Gerais; Brasil
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Materia
LACTIC ACID BACTERIA
INFLAMMATORY BOWEL DISEASE
CATALASE
SUPEROXIDE DISMUTASE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/114317
Acceder
id CONICETDig_446ad43300578ce294b60006575760ae
oai_identifier_str oai:ri.conicet.gov.ar:11336/114317
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseasesLeblanc, Jean Guy Josephdel Carmen, Silvina AndreaAlvarenga Lima, FernandaZurita Turk, MeritxellMiyoshi, AndersonAzevedo, Vascode Moreno, Maria AlejandraLACTIC ACID BACTERIAINFLAMMATORY BOWEL DISEASECATALASESUPEROXIDE DISMUTASEhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Inflammatory bowel disease (IBD) is a term used to describe a group of intestinal disorders in which inflammation is a major feature. Although rare forms of IBD exist, these diseases normally pertain to ulcerative colitis (UC) (Head & Jurenka, 2003) and Crohn’s disease (CD) (Baumgart & Sandborn, 2007). There is evidence that these do not represent distinct conditions but rather are the same disease with shared etiological factors (Price, 1992); however, clinical manifestations (such as the exact location of the pathology or the affected individual’s immunological and constitutional endowment) are distinctive between both. Despite many years of study, the exact etiology and pathogenesis of these disorders remain unclear but great advances have been made using experimental animal models and have provided insights into the complex, multi-factorial processes and mechanisms that can result in chronic intestinal inflammation (Elson & Weaver, 2003). The aim of this chapter is to present an overview of the current expanding knowledge of the mechanisms by which lactic acid bacteria and other probiotic microorganisms participate in the prevention and treatment of IBD and how genetic engineering techniques can be used to improve their effectiveness or create novel therapeutic strains. In the following sections, the mechanisms by which these beneficial microorganisms exert their therapeutic effects, which include changes in the gut microbiota, stimulation of the host immune responses, enhancement of intestinal barrier function and reduction of the oxidative stress due to their antioxidant properties will be discussed.Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Alvarenga Lima, Fernanda. Universidade Federal de Minas Gerais; BrasilFil: Zurita Turk, Meritxell. Universidade Federal de Minas Gerais; BrasilFil: Miyoshi, Anderson. Universidade Federal de Minas Gerais; BrasilFil: Azevedo, Vasco. Universidade Federal de Minas Gerais; BrasilFil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaIntechOpenLule, Godfrey2012info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bookParthttp://purl.org/coar/resource_type/c_3248info:ar-repo/semantics/parteDeLibroapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/114317Leblanc, Jean Guy Joseph; del Carmen, Silvina Andrea; Alvarenga Lima, Fernanda; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases; IntechOpen; 2012; 223-238978-953-307-957-8CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.intechopen.com/articles/show/title/prospective-uses-of-genetically-engineered-lactic-acid-bacteria-for-the-prevention-of-inflammatory-binfo:eu-repo/semantics/altIdentifier/doi/10.5772/26200info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:00Zoai:ri.conicet.gov.ar:11336/114317instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:01.007CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
title Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
spellingShingle Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
Leblanc, Jean Guy Joseph
LACTIC ACID BACTERIA
INFLAMMATORY BOWEL DISEASE
CATALASE
SUPEROXIDE DISMUTASE
title_short Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
title_full Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
title_fullStr Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
title_full_unstemmed Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
title_sort Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases
dc.creator.none.fl_str_mv Leblanc, Jean Guy Joseph
del Carmen, Silvina Andrea
Alvarenga Lima, Fernanda
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
author Leblanc, Jean Guy Joseph
author_facet Leblanc, Jean Guy Joseph
del Carmen, Silvina Andrea
Alvarenga Lima, Fernanda
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
author_role author
author2 del Carmen, Silvina Andrea
Alvarenga Lima, Fernanda
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Lule, Godfrey
dc.subject.none.fl_str_mv LACTIC ACID BACTERIA
INFLAMMATORY BOWEL DISEASE
CATALASE
SUPEROXIDE DISMUTASE
topic LACTIC ACID BACTERIA
INFLAMMATORY BOWEL DISEASE
CATALASE
SUPEROXIDE DISMUTASE
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Inflammatory bowel disease (IBD) is a term used to describe a group of intestinal disorders in which inflammation is a major feature. Although rare forms of IBD exist, these diseases normally pertain to ulcerative colitis (UC) (Head & Jurenka, 2003) and Crohn’s disease (CD) (Baumgart & Sandborn, 2007). There is evidence that these do not represent distinct conditions but rather are the same disease with shared etiological factors (Price, 1992); however, clinical manifestations (such as the exact location of the pathology or the affected individual’s immunological and constitutional endowment) are distinctive between both. Despite many years of study, the exact etiology and pathogenesis of these disorders remain unclear but great advances have been made using experimental animal models and have provided insights into the complex, multi-factorial processes and mechanisms that can result in chronic intestinal inflammation (Elson & Weaver, 2003). The aim of this chapter is to present an overview of the current expanding knowledge of the mechanisms by which lactic acid bacteria and other probiotic microorganisms participate in the prevention and treatment of IBD and how genetic engineering techniques can be used to improve their effectiveness or create novel therapeutic strains. In the following sections, the mechanisms by which these beneficial microorganisms exert their therapeutic effects, which include changes in the gut microbiota, stimulation of the host immune responses, enhancement of intestinal barrier function and reduction of the oxidative stress due to their antioxidant properties will be discussed.
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Alvarenga Lima, Fernanda. Universidade Federal de Minas Gerais; Brasil
Fil: Zurita Turk, Meritxell. Universidade Federal de Minas Gerais; Brasil
Fil: Miyoshi, Anderson. Universidade Federal de Minas Gerais; Brasil
Fil: Azevedo, Vasco. Universidade Federal de Minas Gerais; Brasil
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
description Inflammatory bowel disease (IBD) is a term used to describe a group of intestinal disorders in which inflammation is a major feature. Although rare forms of IBD exist, these diseases normally pertain to ulcerative colitis (UC) (Head & Jurenka, 2003) and Crohn’s disease (CD) (Baumgart & Sandborn, 2007). There is evidence that these do not represent distinct conditions but rather are the same disease with shared etiological factors (Price, 1992); however, clinical manifestations (such as the exact location of the pathology or the affected individual’s immunological and constitutional endowment) are distinctive between both. Despite many years of study, the exact etiology and pathogenesis of these disorders remain unclear but great advances have been made using experimental animal models and have provided insights into the complex, multi-factorial processes and mechanisms that can result in chronic intestinal inflammation (Elson & Weaver, 2003). The aim of this chapter is to present an overview of the current expanding knowledge of the mechanisms by which lactic acid bacteria and other probiotic microorganisms participate in the prevention and treatment of IBD and how genetic engineering techniques can be used to improve their effectiveness or create novel therapeutic strains. In the following sections, the mechanisms by which these beneficial microorganisms exert their therapeutic effects, which include changes in the gut microbiota, stimulation of the host immune responses, enhancement of intestinal barrier function and reduction of the oxidative stress due to their antioxidant properties will be discussed.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/bookPart
http://purl.org/coar/resource_type/c_3248
info:ar-repo/semantics/parteDeLibro
status_str publishedVersion
format bookPart
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/114317
Leblanc, Jean Guy Joseph; del Carmen, Silvina Andrea; Alvarenga Lima, Fernanda; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases; IntechOpen; 2012; 223-238
978-953-307-957-8
CONICET Digital
CONICET
url http://hdl.handle.net/11336/114317
identifier_str_mv Leblanc, Jean Guy Joseph; del Carmen, Silvina Andrea; Alvarenga Lima, Fernanda; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases; IntechOpen; 2012; 223-238
978-953-307-957-8
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.intechopen.com/articles/show/title/prospective-uses-of-genetically-engineered-lactic-acid-bacteria-for-the-prevention-of-inflammatory-b
info:eu-repo/semantics/altIdentifier/doi/10.5772/26200
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv IntechOpen
publisher.none.fl_str_mv IntechOpen
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269555471155200
score 13.13397

Publicaciones similares